<DOC>
	<DOCNO>NCT01389973</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ustekinumab patient primary biliary cirrhosis inadequate response ursodeoxycholic acid .</brief_summary>
	<brief_title>A Study Efficacy Safety Ustekinumab Patients With Primary Biliary Cirrhosis ( PBC ) Who Had Inadequate Response Ursodeoxycholic Acid</brief_title>
	<detailed_description>This multi-center , randomize ( treatment assign chance ) , placebo-controlled ( inactive substance compare test drug see whether drug real effect ) , parallel-group ( two group patient receive different treatment ) study consist two part . Part 1 open-label ( participant know identity treatment ) proof-of-concept study . Part 2 contingent result Part 1 double-blind ( investigator patient know treatment give ) evaluate efficacy safety ustekinumab patient primary biliary cirrhosis ( PBC ) inadequate response ursodeoxycholic acid . The duration participation study individual participant may 216 week . Patient safety monitor . Part 1 : ustekinumab , 90mg subcutaneous ( SC ) Weeks 0 4 every 8 week Week 20 ; Part 2 : Depending Part 1 result , either ( ustekinumab 90mg 45mg placebo ) ( ustekinumab 90mg 180mg placebo ) SC Weeks 0 4 every 8 week Week 20 ; Long-term Extension ( include Part 1 Part 2 ) : begin Week 28 , every 8 week initially assign dose extension dose select ; every 8 week Week 196 select dose .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Have prove likely Primary Biliary Cirrhosis ( PBC ) Be stable dose ursodeoxycholic acid least 6 month prior Week 0 Have screen alkaline phosphatase ( ALP ) level &gt; 1.67 ULN ( upper limit normal ) Have screen laboratory test result within protocolspecified limit Have history latent active tuberculosis ( TB ) prior screen sign symptom suggestive active TB upon medical history and/or physical examination . Has history gastrointestinal bleeding , secondary portal hypertension , hepatic encephalopathy , ascites require treatment diuretic Has screen direct bilirubin &gt; 1.0 mg/dL Has previous liver histology diagnosis steatohepatitis high risk nonalcoholic steatohepatitis Has previous liver histology diagnosis chronic autoimmune hepatitis high risk autoimmune hepatitis overlap syndrome Testing positive surface antigen ( HBsAg+ ) , regardless result hepatitis B test Have use colchicine , methotrexate ( MTX ) , azathioprine ( AZA ) , systemic corticosteroid within 3 month prior first administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diseases [ C ] - Digestive System Diseases [ C06 ]</keyword>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>ursodeoxycholic acid ( UDCA )</keyword>
	<keyword>STELARA</keyword>
	<keyword>ustekinumab</keyword>
</DOC>